Influenza VaccineNCT07157163
Nudge and Motivational Interviewing Interventions to Improve Influenza Vaccine Uptake Among Healthcare Workers in China
A study testing Phase 1: standardized nudge messages, Phase 1: personalized nudge messages + chatbot and Phase 2: motivational Interviewing in people with Influenza Vaccine and Healthcare Workers, run by Centers for Disease Control and Prevention, China.
Trial summary
The goal of this clinical trial is to learn if nudge-based interventions and motivational interviewing work to improve influenza vaccination uptake among healthcare workers in China. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Influenza Vaccine, Healthcare Workers
- What is being tested?
- Phase 1: standardized nudge messages, Phase 1: personalized nudge messages + chatbot and Phase 2: motivational Interviewing
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,050 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2025to Mar 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Full-time employees of community hospitals who remain employed throughout the study period.
- Have not scheduled or received an influenza vaccine between August 2024 and the time of formal enrollment.
- Agree to participate and provide informed consent.
- Healthcare workers from community hospitals who remain unvaccinated after Phase 1, as verified by official records, will be screened.
- A selected subset of these individuals will be invited to participate in Phase 2.
Who cannot join
- Participants with medical conditions that contraindicate influenza vaccination.
- Participants who refuse to participate or do not provide informed consent .
- Phase 2: Individual Randomized Controlled Trial
- Participants who refuse to participate or do not provide informed consent .
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effectiveness of Nudge and Motivational Interviewing Interventions to Improve Influenza Vaccination Uptake Among Healthcare Workers in China: a Two-phase Randomized Controlled Trial
The goal of this clinical trial is to learn if nudge-based interventions and motivational interviewing work to improve influenza vaccination uptake among healthcare workers in China. A two-phase randomized controlled trial will be conducted in community hospitals across China, targeting healthcare workers as participants.
The main questions are:
Read more
Do nudge-based interventions increase vaccination rates among healthcare workers?
Does motivational interviewing increase vaccination compliance among those who remain unvaccinated after the phase 1?
In phase 1, community hospitals will be randomized as units into three arms: standard nudge group, personalized nudge group, and a control group. In phase 2, healthcare workers who remain unvaccinated after phase 1 will be individually randomized to either a motivational interviewing group or a control group.
Participants will:
Be recruited from community hospitals to participate in the study. In phase 1 (at the early stage of the flu season), community hospitals will be randomly assigned to one of three groups: standardized nudge messages, personalized nudge messages with a chatbot, or no reminders.
If still unvaccinated in phase 2 (during peak flu season), healthcare workers will be individually assigned to either motivational interviewing group or receive no extra contact.
Have their vaccination status checked at the end of each phase.
Read the detailed description
A two-phase randomized controlled trial will be conducted to evaluate the effectiveness of multi-component interventions to improve vaccination uptake, targeting healthcare workers in China.
Sample size Phase 1: Cluster-Randomized Controlled Trial The sample size is determined to identify a significant difference in the primary outcome, defined as the influenza vaccination uptake among healthcare workers in community hospital, comparing the intervention and control groups. Historical surveillance data from the three participating cities indicate a baseline vaccination rate of approximately 4% without targeted interventions. The proposed intervention is expected to increase this rate to 10%. A two-sided significance level of α = 0.05 is set, adjusted to α = 0.0167 via Bonferroni correction to account for three planned pairwise comparisons. Statistical power is set at 0.80, with an assumed intraclass correlation coefficient (ICC) of 0.05 and an average cluster size of 50 participants per cluster. Based on these parameters, 23 clusters per study arm are required, resulting in a total of 69 clusters across the three arms. To account for potential attrition, the sample size will be increased to 27 clusters per arm, yielding a total of 81 clusters and an estimated 4,050 participants. All eligible healthcare workers in the participating community hospitals will be included in the study.
Phase 2: Individual Randomized Controlled Trial In phase 2, the target population comprises healthcare workers who remain unvaccinated after Phase 1, from the 54 community hospitals assigned to the intervention arms. Without further intervention, the vaccination uptake rate in this group is estimated to be approximately 3%. The motivational interviewing intervention is expected to increase this rate to 13%. Assuming a two-sided significance level of α = 0.05 and statistical power of 0.80, sample size estimation indicates a minimum of 112 participants per group is required. To ensure feasibility and maintain study power, the motivational interviewing group will aim to enroll 150 participants. Fifteen community hospitals will be randomly selected from the two intervention arms of Phase 1. Control groups are established: 1) healthcare workers from 15 community hospitals selected for the motivational interviewing intervention, excluding approximately 10 individuals per community hospital who receive the intervention, resulting in a control group of approximately 525 healthcare workers; and 2) healthcare workers from the remaining 39 community hospitals not participating in the motivational interviewing intervention, comprising approximately 1,755 individuals. Therefore, the control group in phase 2 comprises approximately 2,280 participants.
In phase 1, a stratified block randomization method will be employed to ensure balanced allocation across study groups. Stratification factors include historical influenza vaccination rates among healthcare workers and the size of the healthcare staff at each community hospital. Community hospitals with comparable levels of these factors are grouped into blocks within each city and then randomly assigned within each block to one of three groups: the standardized nudge group, personalized nudge group, or a control group.
In phase 2, a two-stage random sampling procedure will be used. Specifically, 15 community hospitals will be randomly selected from the 54 hospitals assigned to the intervention groups in the phase 1 (five hospitals per province). Within each selected hospital, 10 healthcare workers who remained unvaccinated after the first-phase intervention will be randomly sampled and enrolled in the individual-level intervention study.
Qualitative interviews and a baseline survey will be conducted before the interventions. Follow-up questionnaires will be completed two weeks after the end of each intervention phase. The primary outcome is the receipt of influenza vaccination by healthcare workers, which will be assessed two months after each intervention phase using official vaccination records.
The intention-to-treat (ITT) analysis will be used to evaluate the effectiveness of the interventions. The primary outcome is influenza vaccine uptake among healthcare workers post-intervention. Vaccine uptake will be compared between intervention and control groups, and across intervention arms, using chi-square tests. To account for clustering and adjust for potential confounders, generalized estimating equation (GEE) models will be employed to provide robust effect estimates. Timing of vaccination will be evaluated using Kaplan-Meier survival curves and log-rank tests, with Cox proportional hazards models to estimate intervention effects on time-to-vaccination. Subgroup analyses will assess heterogeneity of intervention effects across populations stratified by baseline characteristics.
Secondary outcomes will be evaluated at baseline and post-intervention. Between-group comparisons, including intervention versus control and across intervention arms, will use t-tests for continuous variables and chi-square tests for categorical variables. GEE models with repeated measures will assess intervention effects on secondary outcomes, adjusting for relevant covariates. Subgroup analyses will examine differential effects across subpopulations defined by baseline factors.
- Conditions
- Influenza Vaccine, Healthcare Workers
- Being tested
- Phase 1: standardized nudge messages, Phase 1: personalized nudge messages + chatbot, Phase 2: motivational Interviewing
- Medical subject headings
- Influenza, Human
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Phase 1: standardized nudge messagesBehavioural
Participants receive uniform messages designed to encourage influenza vaccination. These messages, grounded in nudge theory, are delivered through a Chinese online platform to promote vaccination uptake.
Phase 1: personalized nudge messages + chatbotBehavioural
Participants receive tailored messages designed to encourage influenza vaccination. These messages, grounded in nudge theory, are delivered through a Chinese online platform to promote vaccination uptake. Additionally, they have access to an interactive chatbot to address questions and provide decision-making support for influenza vaccination.
Phase 2: motivational InterviewingBehavioural
Unvaccinated participants engage in one-on-one motivational interviewing sessions with a trained interviewer.
| Study group | Role | What they receive |
|---|---|---|
| Phase 1: standardized nudge group | Experimental | Participants receive uniform nudge messages. Receives: Behavioral: Phase 1: standardized nudge messages |
| Phase 1: personalized nudge group | Experimental | Participants receive tailored nudge messages with access to a chatbot. Receives: Behavioral: Phase 1: personalized nudge messages + chatbot |
| Phase 1: control group | No intervention | Participants receive no study-related interventions. |
| Phase 2: motivational interviewing group | Experimental | Participants receive motivational interviewing. Receives: Behavioral: Phase 2: motivational Interviewing |
| Phase 2: control group | No intervention | Participants receive no study-related interventions. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Influenza vaccination uptake
whether participants get vaccinated against influenza, measured by official vaccination system
Measured: 2 months post-intervention for each study phase.
Secondary outcomes (6)
Influenza vaccine literacy
A series of questions about influenza vaccine knowledge and misinformation. Total literacy score is calculated based on the number of questions answered correctly by the participants.
Measured: Baseline (pre-intervention) and 2 weeks after each intervention phase.
Influenza vaccine confidence
Vaccine confidence index (VCI), including participants' confidence in the importance, effectiveness, and safety of the influenza vaccine, and trust in public health agency. Responses will be measured using a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree).
Measured: Baseline (pre-intervention) and 2 weeks after each intervention phase.
High perception on influenza risk
Proportion of participants who perceived to be susceptible and severe to influenza.
Measured: Baseline (pre-intervention) and 2 weeks after each intervention phase.
Influenza vaccination intention
Participants' intention to receive influenza vaccine. Unit of Measure: Influenza Vaccination Intention 5-point Likert scale score, 1-5 (higher scores indicate stronger intention).
Measured: Baseline (pre-intervention) and 2 weeks after each intervention phase.
Recommendation of influenza vaccine to the public.
Recommendation frequency of influenza vaccine to the public during the health care. Unit of Measure:Recommendation frequency score, 1-5 (higher scores indicate more frequent recommendations).
Measured: Baseline (pre-intervention) and 2 weeks after each intervention phase.
Access to professional information of influenza vaccine
Whether professional information about influenza vaccine is provided in the workplace.
Measured: Baseline (pre-intervention) and 2 weeks after each intervention phase.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2025
- Study start1 Sep 2025 (estimated)
- Primary completionMar 2026 (estimated)
- Study completionMar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Influenza VaccineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 4,050 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centers for Disease Control and Prevention, China
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Lixin Hao, Centers for Disease Control and Prevention, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07157163
- Sponsor's protocol ID
- 202529
- Status last verified
- Sep 2025
- First submitted
- 19 Aug 2025
- Last updated
- 11 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to participant privacy concerns and institutional data protection policies.
Publications
Wang Q, Hou Q, Xu H, Ma R, An Z, Hao L, Hou Z, Yin Z. Effectiveness of nudge and motivational interview interventions to improve influenza vaccine uptake among healthcare workers in China: study protocol for a two-phase randomized trial. Trials. 2026 Apr 20;27(1):404. doi: 10.1186/s13063-026-09658-8.
PubMed 42010692
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Nudge and Motivational Interviewing Interventions to Improve Influenza Vaccination Uptake Among Healthcare Workers in China: a Two-phase Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07157163
- Acronym / sponsor ID
- 202529
- Conditions
- Influenza Vaccine, Healthcare Workers
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 4,050 participants (estimated)
- Lead sponsor
- Centers for Disease Control and Prevention, ChinaOther government
- Study start
- 1 Sep 2025 (estimated)
- Primary completion
- Mar 2026 (estimated)
- Study completion
- Mar 2026 (estimated)
- First posted
- 5 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if nudge-based interventions and motivational interviewing work to improve influenza vaccination uptake among healthcare workers in China. A two-phase randomized controlled trial will be conducted in community hospitals across China, targeting healthcare workers as participants.
The main questions are:
Do nudge-based interventions increase vaccination rates among healthcare workers?
Does motivational interviewing increase vaccination compliance among those who remain unvaccinated after the phase 1?
In phase 1, community hospitals will be randomized as units into three arms: standard nudge group, personalized nudge group, and a control group. In phase 2, healthcare workers who remain unvaccinated after phase 1 will be individually randomized to either a motivational interviewing group or a control group.
Participants will:
Be recruited from community hospitals to participate in the study. In phase 1 (at the early stage of the flu season), community hospitals will be randomly assigned to one of three groups: standardized nudge messages, personalized nudge messages with a chatbot, or no reminders.
If still unvaccinated in phase 2 (during peak flu season), healthcare workers will be individually assigned to either motivational interviewing group or receive no extra contact.
Have their vaccination status checked at the end of each phase.
Detailed description
A two-phase randomized controlled trial will be conducted to evaluate the effectiveness of multi-component interventions to improve vaccination uptake, targeting healthcare workers in China.
Sample size Phase 1: Cluster-Randomized Controlled Trial The sample size is determined to identify a significant difference in the primary outcome, defined as the influenza vaccination uptake among healthcare workers in community hospital, comparing the intervention and control groups. Historical surveillance data from the three participating cities indicate a baseline vaccination rate of approximately 4% without targeted interventions. The proposed intervention is expected to increase this rate to 10%. A two-sided significance level of α = 0.05 is set, adjusted to α = 0.0167 via Bonferroni correction to account for three planned pairwise comparisons. Statistical power is set at 0.80, with an assumed intraclass correlation coefficient (ICC) of 0.05 and an average cluster size of 50 participants per cluster. Based on these parameters, 23 clusters per study arm are required, resulting in a total of 69 clusters across the three arms. To account for potential attrition, the sample size will be increased to 27 clusters per arm, yielding a total of 81 clusters and an estimated 4,050 participants. All eligible healthcare workers in the participating community hospitals will be included in the study.
Phase 2: Individual Randomized Controlled Trial In phase 2, the target population comprises healthcare workers who remain unvaccinated after Phase 1, from the 54 community hospitals assigned to the intervention arms. Without further intervention, the vaccination uptake rate in this group is estimated to be approximately 3%. The motivational interviewing intervention is expected to increase this rate to 13%. Assuming a two-sided significance level of α = 0.05 and statistical power of 0.80, sample size estimation indicates a minimum of 112 participants per group is required. To ensure feasibility and maintain study power, the motivational interviewing group will aim to enroll 150 participants. Fifteen community hospitals will be randomly selected from the two intervention arms of Phase 1. Control groups are established: 1) healthcare workers from 15 community hospitals selected for the motivational interviewing intervention, excluding approximately 10 individuals per community hospital who receive the intervention, resulting in a control group of approximately 525 healthcare workers; and 2) healthcare workers from the remaining 39 community hospitals not participating in the motivational interviewing intervention, comprising approximately 1,755 individuals. Therefore, the control group in phase 2 comprises approximately 2,280 participants.
In phase 1, a stratified block randomization method will be employed to ensure balanced allocation across study groups. Stratification factors include historical influenza vaccination rates among healthcare workers and the size of the healthcare staff at each community hospital. Community hospitals with comparable levels of these factors are grouped into blocks within each city and then randomly assigned within each block to one of three groups: the standardized nudge group, personalized nudge group, or a control group.
In phase 2, a two-stage random sampling procedure will be used. Specifically, 15 community hospitals will be randomly selected from the 54 hospitals assigned to the intervention groups in the phase 1 (five hospitals per province). Within each selected hospital, 10 healthcare workers who remained unvaccinated after the first-phase intervention will be randomly sampled and enrolled in the individual-level intervention study.
Qualitative interviews and a baseline survey will be conducted before the interventions. Follow-up questionnaires will be completed two weeks after the end of each intervention phase. The primary outcome is the receipt of influenza vaccination by healthcare workers, which will be assessed two months after each intervention phase using official vaccination records.
The intention-to-treat (ITT) analysis will be used to evaluate the effectiveness of the interventions. The primary outcome is influenza vaccine uptake among healthcare workers post-intervention. Vaccine uptake will be compared between intervention and control groups, and across intervention arms, using chi-square tests. To account for clustering and adjust for potential confounders, generalized estimating equation (GEE) models will be employed to provide robust effect estimates. Timing of vaccination will be evaluated using Kaplan-Meier survival curves and log-rank tests, with Cox proportional hazards models to estimate intervention effects on time-to-vaccination. Subgroup analyses will assess heterogeneity of intervention effects across populations stratified by baseline characteristics.
Secondary outcomes will be evaluated at baseline and post-intervention. Between-group comparisons, including intervention versus control and across intervention arms, will use t-tests for continuous variables and chi-square tests for categorical variables. GEE models with repeated measures will assess intervention effects on secondary outcomes, adjusting for relevant covariates. Subgroup analyses will examine differential effects across subpopulations defined by baseline factors.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Phase 1: standardized nudge group | Experimental | Behavioral: Phase 1: standardized nudge messagesParticipants receive uniform nudge messages. |
| Phase 1: personalized nudge group | Experimental | Behavioral: Phase 1: personalized nudge messages + chatbotParticipants receive tailored nudge messages with access to a chatbot. |
| Phase 1: control group | No intervention | –Participants receive no study-related interventions. |
| Phase 2: motivational interviewing group | Experimental | Behavioral: Phase 2: motivational InterviewingParticipants receive motivational interviewing. |
| Phase 2: control group | No intervention | –Participants receive no study-related interventions. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Full-time employees of community hospitals who remain employed throughout the study period.
- Have not scheduled or received an influenza vaccine between August 2024 and the time of formal enrollment.
- Agree to participate and provide informed consent.
- Healthcare workers from community hospitals who remain unvaccinated after Phase 1, as verified by official records, will be screened.
- A selected subset of these individuals will be invited to participate in Phase 2.
Key exclusion criteria (4 listed)
- Participants with medical conditions that contraindicate influenza vaccination.
- Participants who refuse to participate or do not provide informed consent .
- Phase 2: Individual Randomized Controlled Trial
- Participants who refuse to participate or do not provide informed consent .
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Phase 1: standardized nudge messagesParticipants receive uniform messages designed to encourage influenza vaccination. These messages, grounded in nudge theory, are delivered through a Chinese online platform to promote vaccination uptake. | Behavioural | Phase 1: standardized nudge group |
| Phase 1: personalized nudge messages + chatbotParticipants receive tailored messages designed to encourage influenza vaccination. These messages, grounded in nudge theory, are delivered through a Chinese online platform to promote vaccination uptake. Additionally, they have access to an interactive chatbot to address questions and provide decision-making support for influenza vaccination. | Behavioural | Phase 1: personalized nudge group |
| Phase 2: motivational InterviewingUnvaccinated participants engage in one-on-one motivational interviewing sessions with a trained interviewer. | Behavioural | Phase 2: motivational interviewing group |
Primary outcome
Influenza vaccination uptake
Time frame: 2 months post-intervention for each study phase.
whether participants get vaccinated against influenza, measured by official vaccination system
6 secondary outcomes
Influenza vaccine literacy
Time frame: Baseline (pre-intervention) and 2 weeks after each intervention phase.
Influenza vaccine confidence
Time frame: Baseline (pre-intervention) and 2 weeks after each intervention phase.
High perception on influenza risk
Time frame: Baseline (pre-intervention) and 2 weeks after each intervention phase.
Influenza vaccination intention
Time frame: Baseline (pre-intervention) and 2 weeks after each intervention phase.
Recommendation of influenza vaccine to the public.
Time frame: Baseline (pre-intervention) and 2 weeks after each intervention phase.
Access to professional information of influenza vaccine
Time frame: Baseline (pre-intervention) and 2 weeks after each intervention phase.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
- Derived from this study: PubMed 42010692Wang Q, Hou Q, Xu H, Ma R, An Z, Hao L, Hou Z, Yin Z. Effectiveness of nudge and motivational interview interventions to improve influenza vaccine uptake among healthcare workers in China: study protocol for a two-phase randomized trial. Trials. 2026 Apr 20;27(1):404. doi: 10.1186/s13063-026-09658-8.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to participant privacy concerns and institutional data protection policies.
Related trials for Influenza Vaccine
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
RecruitingPhase 2
BPL-1357 Against H1N1 Influenza Virus Challenge
Influenza, Human
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
RecruitingPhase 1
pH1N1 Blinded Challenge Study
Influenza
RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Phase 1: standardized nudge messages, Phase 1: personalized nudge messages + chatbot and Phase 2: motivational Interviewing in people with Influenza Vaccine and Healthcare Workers, run by Centers for Disease Control and Prevention, China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lixin Hao, PhD (+86 15201347661, haolx@chinacdc.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Influenza vaccination uptake (time frame: 2 months post-intervention for each study phase.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07157163, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.